JPH0647530B2 - Pharmaceutical capsules for intestinal diseases and method for producing the same - Google Patents
Pharmaceutical capsules for intestinal diseases and method for producing the sameInfo
- Publication number
- JPH0647530B2 JPH0647530B2 JP2364090A JP2364090A JPH0647530B2 JP H0647530 B2 JPH0647530 B2 JP H0647530B2 JP 2364090 A JP2364090 A JP 2364090A JP 2364090 A JP2364090 A JP 2364090A JP H0647530 B2 JPH0647530 B2 JP H0647530B2
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- drug
- intestine
- alginic acid
- polyhydric alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、食道や胃を刺激したり、胃内で変質すること
なく、十二脂腸、小腸及び大腸に直接薬剤を作用させた
い場合に使用される腸疾患用薬剤入りカプセル及びその
製法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial field of application] The present invention is intended for the case where a drug is directly applied to the duodenum, small intestine and large intestine without irritating the esophagus or stomach or deteriorating in the stomach. The present invention relates to a drug-containing capsule for enteropathy and a method for producing the same.
十二脂腸、小腸、大腸に発生した潰瘍、癌、腸結核、分
泌不全などの腸内疾患において薬剤を投与するには経口
投与、肝門投与、注射などの手段がある。There are means such as oral administration, hepatic hilum administration, and injection for administering the drug in enteric diseases such as ulcers occurring in the duodenum, small intestine, large intestine, cancer, intestinal tuberculosis, and secretory insufficiency.
経口投与は簡便であるが、腸に達する以前に胃を通過す
るとき、胃は強酸性下に消化液が充分に供給されている
ため、薬剤が変質したり効力が低下し、或いは薬剤が胃
を刺激するとか、その薬剤の刺激により潰瘍を生じるお
それがあった。したがって、経口投与が不可能な薬剤の
場合には注射による投与が行われるが、この場合は全身
に供給されるため、不必要な器官に薬剤が分散し効果的
治療が行われ難いばかりでなく、他の器官が薬剤の副作
用を受けるという問題があった。Oral administration is simple, but when it passes through the stomach before it reaches the intestine, the stomach is sufficiently supplied with digestive juice under strong acidity, so that the drug is altered or the efficacy is reduced, or There is a risk of ulcers due to irritation of the drug or stimulation of the drug. Therefore, in the case of a drug that cannot be administered orally, it is administered by injection, but in this case, it is supplied systemically, so that the drug is dispersed in unnecessary organs and effective treatment is not only difficult. However, there was a problem that other organs received side effects of the drug.
そこで、経口的に投与された腸疾患治療用薬剤或いは腸
疾患予防用薬剤を、胃液に接触することなく胃内を通過
させ、腸内すなわち、十二脂腸、小腸、大腸等、目的と
する器官に到達させ、腸内で放出される薬剤の量を調節
し、目的、薬剤の種類に応じた速度で放出させる技術が
求められていた。Therefore, an orally administered drug for treating intestinal disease or drug for preventing intestinal disease is passed through the stomach without contact with the gastric juice to obtain the intestine, that is, the duodenum, small intestine, large intestine, etc. There has been a demand for a technique of controlling the amount of the drug that reaches the organ and releasing it in the intestine, and releasing the drug at a rate according to the purpose and the type of the drug.
本発明は上記課題を解決するものであって、その構成
は、多価アルコール、糖アルコール、単糖類、二糖類及
びオリゴ糖から選ばれた少なくとも１種の原液或いは濃
厚溶液中で、カラギナン、アルギン酸、アルギン酸誘導
体、寒天、ローカストビーンガム、グアーガム、タマリ
ンド種子多糖類、ペクチン、キサンタンガム、グルコマ
ンナン、キチン質及びプルランから選ばれた少なくとも
１種の天然多糖類を、アルカリの存在下或いは非存在下
に、均一に混練して得られた天然多糖類・多価アルコー
ル組成物からなる難消化可食性高分子化合物の溶液を用
いてカプセルを形成し、カプセル形成と同時にまたはカ
プセル形成後に、該カプセルに薬剤が通過できる複数の
孔を穿設するか、或いは小腸内において穿設可能とし、
該カプセル内に腸疾患用薬剤を収納し、しかる後該カプ
セルを融点３５℃以上で胃液により分解され難い素材で
被覆することを特徴とする。The present invention is to solve the above-mentioned problems, and its constitution is carrageenan and alginic acid in at least one stock solution or concentrated solution selected from polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides. , Alginic acid derivative, agar, locust bean gum, guar gum, tamarind seed polysaccharide, at least one natural polysaccharide selected from pectin, xanthan gum, glucomannan, chitin and pullulan in the presence or absence of alkali. A capsule is formed using a solution of an indigestible edible polymer compound composed of a natural polysaccharide / polyhydric alcohol composition obtained by uniformly kneading, and the capsule is formed with the drug at the same time as or after the capsule formation. A plurality of holes that allow passage through, or can be drilled in the small intestine,
It is characterized in that a drug for intestinal diseases is stored in the capsule, and then the capsule is coated with a material having a melting point of 35 ° C. or higher and which is hardly decomposed by gastric juice.
本発明において、腸とは十二脂腸から肛門に至るまでの
部位であり、特に十二脂腸、小腸、大腸である。腸内疾
患としては、クローン病、潰瘍、腸結核、癌等が挙げら
れるがこれらに限定されるものではない。In the present invention, the intestine is a part from the duodenum to the anus, and particularly the duodenum, small intestine, and large intestine. Enteric diseases include, but are not limited to, Crohn's disease, ulcers, intestinal tuberculosis, cancer and the like.
薬剤は粘膜の保護剤、制癌剤、抗癌剤、抗生物質、整腸
剤、消化性潰瘍剤などがある。これらの薬剤はカプセル
に収納する。カプセルは更にその表面を胃液で分解され
難い素材、すなわち、融点３５℃以上の食用硬化油脂や
メタクリル酸とアクリル酸の乳化重合物等で被覆する。
したがって、胃内における消化のおそれはないが、胃内
で破袋しないだけの剛性或いは強度を有する可食性物質
である。十二脂腸や小腸の前部で作用させる薬剤の場合
には、胃を通過後速やかに放出させるために、カプセル
自体に多くの大型穿孔を設け、外皮の素材が分解剥離し
た後は内容薬剤が速やかに放出されるようにする。Drugs include mucosal protective agents, anti-cancer agents, anti-cancer agents, antibiotics, intestinal agents, peptic ulcer agents and the like. These drugs are stored in capsules. The surface of the capsule is further coated with a material that is not easily decomposed by gastric juice, that is, edible hardened oil and fat having a melting point of 35 ° C. or higher, an emulsion polymer of methacrylic acid and acrylic acid, and the like.
Therefore, it is an edible substance having a rigidity or strength that does not cause bag breakage in the stomach, although there is no risk of digestion in the stomach. In the case of drugs that act on the anterior part of the duodenum or small intestine, many large perforations are provided in the capsule itself in order to promptly release it after passing through the stomach, and after the material of the outer skin is decomposed and peeled off, the content drug To be released promptly.
一方、大腸や小腸の後部で作用させたい薬剤の場合に
は、カプセルに微細な穿孔を設けることが重要である。
穿孔の大きさは薬剤が大腸の全域にわたって均等に放出
され、肛門から排出されるときには内部にほとんど薬剤
が残存しない状態が好ましい。On the other hand, in the case of a drug which is desired to act in the posterior portion of the large intestine or the small intestine, it is important to provide the capsule with fine perforations.
The size of the perforations is preferably such that the drug is evenly released over the entire large intestine and almost no drug remains inside when discharged from the anus.
難消化性の素材としては、例えば、特開昭６３−２８３
８０号や、特開昭６３−１６４８５８号に開示された多
価アルコール、糖アルコール、単糖類、二糖類及びオリ
ゴ糖から選ばれた少なくとも１種の濃厚溶液の中で、カ
ラギナン、アルギン酸、アルギン酸誘導体、寒天、ロー
カストビーンガム、グアーガム、タマリンド種子多糖
類、ペクチン、キサンタンガム、グルコマンナン、キチ
ン質、プルランから選ばれた少なくとも１種の天然多糖
類をアルカリの存在下または非存在下に、加熱しながら
均一に混練して得られた天然多糖類・多価アルコール組
成物を用いる。この組成物は胃腸において消化されるこ
とがなく、耐水性で肛門から排出されるまでその形状を
維持する。Examples of the indigestible material include, for example, JP-A-63-283.
Carrageenan, alginic acid and alginic acid derivatives in a concentrated solution of at least one selected from polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides disclosed in JP-A No. , Agar, locust bean gum, guar gum, tamarind seed polysaccharide, pectin, xanthan gum, glucomannan, chitin, pullulan at least one natural polysaccharide selected in the presence or absence of alkali while heating. A natural polysaccharide / polyhydric alcohol composition obtained by uniformly kneading is used. The composition is not digested in the gastrointestinal tract, is water resistant and retains its shape until drained from the anus.
カプセルの製法としては、例えば、上記素材の濃厚水溶
液にカプセルの型を浸漬し、乾燥させてもよく、前もっ
て製造したシートを加熱圧縮して一定の型に成形しても
よい。更には、薬剤自体を上記の組成物を用いて顆粒状
とすることも可能である。As a method for producing the capsule, for example, the capsule die may be dipped in a concentrated aqueous solution of the above material and dried, or the sheet produced in advance may be heated and compressed to be formed into a certain die. Further, the drug itself can be made into a granule by using the above composition.
カプセルには複数の微細な孔を穿設する。孔の大きさは
素材の種類、厚さ、特に作用させたい腸内部位によって
も異なるが内部の薬剤が自由に通過できる大きさであ
り、０．１〜５μ、好ましくは０．５〜３μである。孔
を設けるにあたっては、カプセルの型内に複数の針状物
を自由に突出させたり、収納したりできる装置を設けカ
プセル成形の際は突出させ、脱型の際は収納させればカ
プセル成形と同時に複数の孔を設けることができる。或
いはカプセル成形後に孔を設けてもよく、熱針による機
械的方法、レーザービーム等による方法もある。更に、
消化性素材の粒子を非消化性のカプセル素材に混合して
カプセルを成形してもよい。この場合は孔を有しないカ
プセルであるが、小腸内において消化性素材が消化消滅
し、その後に複数の孔が穿設される。この場合には、消
化性素材の粒子は少なくとも薬剤が自由に通過できる大
きさであることを要する。ただし、被覆膜が半透膜であ
る場合には、薬剤の種類によっては穿孔が存在しなくと
も薬剤を放出することができるものもある。The capsule is provided with a plurality of fine holes. The size of the pores depends on the type and thickness of the material, and especially on the intestinal site to be acted on, but the size allows free passage of the drug inside, and is 0.1-5μ, preferably 0.5-3μ. is there. When forming the holes, a device that allows the needles to freely project or store a plurality of needle-shaped objects in the mold of the capsule is provided so that they are projected when the capsule is molded and stored when the mold is removed. Multiple holes can be provided at the same time. Alternatively, holes may be provided after capsule formation, and there are also a mechanical method using a hot needle and a method using a laser beam. Furthermore,
Particles of digestible material may be mixed with non-digestible capsule material to form capsules. In this case, the capsule has no holes, but the digestible material is digested and extinguished in the small intestine, and then a plurality of holes are formed. In this case, the particles of the digestible material need to be at least large enough for the drug to pass through. However, when the coating film is a semipermeable membrane, there are some types that can release the drug depending on the type of the drug even without the perforation.
更に胃内通過中にカプセル中に胃液が浸透するのを防ぐ
ために、カプセル外表面を胃液で分解され難い素材で緻
密に被覆する。このような素材として、例えば、食用硬
化油脂の場合、胃内温度により脱落しない溶融温度を要
し、３５℃以上、好ましくは、４０℃、より好ましくは
４５〜６０℃である。Furthermore, in order to prevent the gastric juice from penetrating into the capsule during passage through the stomach, the outer surface of the capsule is densely coated with a material that is not easily decomposed by the gastric juice. As such a material, for example, in the case of hardened edible fats and oils, a melting temperature that does not fall off due to the temperature in the stomach is required, and it is 35 ° C or higher, preferably 40 ° C, and more preferably 45 to 60 ° C.
このようにしてカプセルは胃液の直接接触から保護され
て腸内に到達する。腸内において油脂は胃リバーゼ、腸
リバーゼ、膵リパーゼ、胆汁などの作用により消化さ
れ、カプセルが露出する。カプセルの穿孔の大きさと単
位面積当たりの穿孔数によって薬剤の放出度がコントロ
ールされ、穿孔の径が大きいかまたは密度が高い場合に
は小腸内で内容薬剤はすべて放出され、小腸前部におい
て薬剤の効果が発現される。In this way the capsule reaches the intestine protected from direct contact with gastric juice. In the intestines, oils and fats are digested by the action of gastric lipase, intestinal lipase, pancreatic lipase, bile, etc., and the capsules are exposed. The release rate of the drug is controlled by the size of the perforations in the capsule and the number of perforations per unit area.When the diameter of the perforations is large or the density is high, all the drug contained in the small intestine is released, and the drug is released in the anterior part of the small intestine. The effect is expressed.
一方、小腸の後部や大腸内で作用させたい薬剤の場合に
は、小腸内での放出を最小に止め、大腸まで到達させる
ため、カプセルに微細な孔を低密度で穿設する。小腸の
滞留時間に比して大腸の滞留時間は極端に長いため、多
少の薬剤は小腸で放出されるが、大部分は大腸において
放出され、大腸の蠕動、大腸内容物の圧力によりカプセ
ルが押しつぶされ、肛門から排出されるまでにほとんど
の内容薬剤を放出する。On the other hand, in the case of a drug desired to act in the posterior part of the small intestine or in the large intestine, in order to minimize the release in the small intestine and reach the large intestine, fine holes are formed in the capsule at low density. Since the retention time of the large intestine is extremely long compared to the retention time of the small intestine, some drugs are released in the small intestine, but most are released in the large intestine, and the capsule is crushed by the peristalsis of the large intestine and the pressure of the large intestine contents. It releases most of its drug content by the time it is expelled from the anus.
本発明は、腸疾患用薬剤を難消化可食性カプセルに収納
し、これを胃酸から保護するために胃内温度で溶解しな
い可食性物質で被覆したものである。小腸に到達後は被
覆物質は消化され、カプセルより内容薬剤が放出され
る。この際、難消化性のカプセルに任意の通過孔を穿設
することにより、薬剤は徐々に放出され、経口的に腸疾
患用薬剤を直接腸内に作用させることが可能になった。According to the present invention, a drug for intestinal diseases is contained in an indigestible edible capsule and is coated with an edible substance that does not dissolve at gastric temperature in order to protect it from gastric acid. After reaching the small intestine, the coating substance is digested and the drug content is released from the capsule. At this time, by forming an arbitrary passage hole in the indigestible capsule, the drug was gradually released, and it became possible to orally act the drug for enteropathy directly in the intestine.
以下の実施例における腸疾患用薬剤の放出試験として
は、真島英信、生理学、文光堂版、４１８〜４４６頁を
参照した。すなわち、試験経過時間として、胃部３０
分、小腸（十二指腸から盲腸）４時間、大腸（盲腸から
直腸）１３時間３０分とした。実施例においては試験時
間を２部分に大別し、胃部３０分、腸部１７時間３０分
の合計１８時間とした。Refer to Hidenobu Mashima, Physiology, Bunkodo Edition, pages 418-446 for the release test of the drug for intestinal diseases in the following examples. That is, as the elapsed test time, the stomach 30
Minutes, small intestine (duodenum to cecum) 4 hours, large intestine (cecum to rectum) 13 hours 30 minutes. In the examples, the test time was roughly divided into 2 parts, and the total time was 18 hours for 30 minutes in the stomach and 17 hours 30 minutes in the intestine.
試験液は日本薬局方１０、一般試験境法、７３４頁によ
る第１液（pH約１．２……胃液相当）、第２液（pH約
６．８……腸液相当）を用い、更に食用油脂被膜を溶解
する目的でリパーゼを添加した。As the test liquid, the first liquid (pH about 1.2 ... corresponding to gastric juice) and the second liquid (pH about 6.8 ... corresponding to intestinal fluid) according to Japanese Pharmacopoeia 10, General Test Boundary, page 734, are further used for food. Lipase was added for the purpose of dissolving the oil and fat film.
試験後、第２液中に放出された薬剤の確認には、試験終
了後の試験液中の薬剤の含有量及び総力価を測定した。After the test, in order to confirm the drug released in the second liquid, the content of the drug and the total titer in the test liquid after the test were measured.
実施例１ カラギナン６０重量部、アルギン酸２０重量部、ローカ
ストビーンガム１０重量部、グルコマンナン１０重量部
を混練し、これにグリセリン３０重量部を加えて８０℃
で良く混合し、しめり気のある粉状の天然多糖類・多価
アルコール組成物を得た。Example 1 60 parts by weight of carrageenan, 20 parts by weight of alginic acid, 10 parts by weight of locust bean gum, and 10 parts by weight of glucomannan were kneaded, and 30 parts by weight of glycerin was added thereto to obtain 80 ° C.
And mixed well to obtain a powdery natural polysaccharide / polyhydric alcohol composition having a firm texture.
この組成物３重量部を９７重量部の水に溶解して粘稠な
溶液とし、この溶液を複数の針が遠隔操作で自由に突出
し、収納される装置のついたカプセル成形機を用いて平
均膜厚５０〜１００μのカプセルを製造した。このカプ
セルは耐熱性であり、孔の大きさは０．５〜３μであっ
た。このカプセルに塩酸テトラサイクリン１０mg（力
価）を挿入し、カプセル末端を熱融着して密封した。次
いで、融点４０℃±２℃の食用硬化油脂（ショートニン
グ精製牛油、横関油脂工業（株）製）を被覆した。3 parts by weight of this composition was dissolved in 97 parts by weight of water to form a viscous solution, and the solution was averaged using a capsule molding machine equipped with a device in which a plurality of needles were freely projected by remote control. Capsules with a film thickness of 50-100 μm were produced. The capsule was heat resistant and had a pore size of 0.5 to 3 μ. Tetracycline hydrochloride 10 mg (titer) was inserted into this capsule, and the end of the capsule was heat-sealed and sealed. Then, a hardened edible oil and fat having a melting point of 40 ° C. ± 2 ° C. (shortening refined beef oil, manufactured by Yokozeki Yushi Kogyo Co., Ltd.) was coated.
このカプセルを第１液５０ml中、３７℃３０分間浸漬
し、次いで第２液２５０mlに１７時間３０分浸漬した。
第２液には市販のリパーゼ（天野製薬（株）製）０．１
ｇを添加した。浸漬終了後、浸漬液中１mlの力価を測定
し、浸漬液の総容量を乗じて腸内で作用した塩酸テトラ
サイクリンの力価を測定した。その結果、塩酸テトラサ
イクリンの力価の９５％が測定された。This capsule was immersed in 50 ml of the first liquid at 37 ° C. for 30 minutes, and then in 250 ml of the second liquid for 17 hours and 30 minutes.
Commercially available lipase (manufactured by Amano Pharmaceutical Co., Ltd.) 0.1
g was added. After the completion of the immersion, the titer of 1 ml in the immersion liquid was measured, and the total volume of the immersion liquid was multiplied to determine the titer of tetracycline hydrochloride acting in the intestine. As a result, 95% of the titer of tetracycline hydrochloride was measured.
実施例２ 融点４０℃±５℃の食用硬化油脂（食用精製加工油脂、
横関油脂工業（株）製）を被覆した以外は実施例１と同
様にして試験を行った。その結果、塩酸テトラサイクリ
ンの力価の９１％が測定された。Example 2 Hardened edible fats and oils having a melting point of 40 ° C. ± 5 ° C. (refined edible processed fats and oils,
The test was conducted in the same manner as in Example 1 except that the coating was carried out by Yokozeki Yushi Kogyo Co., Ltd. As a result, 91% of the titer of tetracycline hydrochloride was measured.
本発明により、腸疾患用薬剤を胃液による分解、作用の
低下或いは胃に対する刺激を排除して、腸内に到達させ
ることが可能になり、各種薬剤を直接腸内の任意の部位
に作用させることが可能になり腸疾患の効果的治療、予
防が容易になった。INDUSTRIAL APPLICABILITY According to the present invention, it becomes possible to allow a drug for intestinal disease to reach the intestine by decomposing gastric juice, reducing the action or stimulating the stomach, and allowing various drugs to act directly on any site in the intestine. This enabled effective treatment and prevention of intestinal diseases.
Claims (3)
二糖類及びオリゴ糖から選ばれた少なくとも１種の原液
或いは濃厚溶液中で、カラギナン、アルギン酸、アルギ
ン酸誘導体、寒天、ローカストビーンガム、グアーガ
ム、タマリンド種子多糖類、ペクチン、キサンタンガ
ム、グルコマンナン、キチン質及びプルランから選ばれ
た少なくとも１種の天然多糖類を、アルカリの存在下或
いは非存在下に、均一に混練して得られた天然多糖類・
多価アルコール組成物からなる難消化性可食性カプセル
内に、腸に作用する薬剤が収納され、該カプセルが融点
３５℃以上で、胃液により分解され難い素材で被覆され
ていることを特徴とする腸疾患用薬剤カプセル。1. A polyhydric alcohol, a sugar alcohol, a monosaccharide,
Carrageenan, alginic acid, alginic acid derivative, agar, locust bean gum, guar gum, tamarind seed polysaccharide, pectin, xanthan gum, glucomannan, chitin and at least one stock solution or concentrated solution selected from disaccharides and oligosaccharides. A natural polysaccharide obtained by uniformly kneading at least one natural polysaccharide selected from pullulan in the presence or absence of an alkali.
A drug which acts on the intestine is contained in an indigestible edible capsule made of a polyhydric alcohol composition, and the capsule has a melting point of 35 ° C. or higher and is coated with a material that is not easily decomposed by gastric juice. Drug capsule for intestinal diseases.
ていることを特徴とする特許請求の範囲第１項記載の腸
疾患用薬剤カプセル。2. The drug capsule for enteric diseases according to claim 1, wherein the indigestible edible capsule is provided with perforations.
二糖類及びオリゴ糖から選ばれた少なくとも１種の原液
或いは濃厚溶液中で、カラギナン、アルギン酸、アルギ
ン酸誘導体、寒天、ローカストビーンガム、グアーガ
ム、タマリンド種子多糖類、ペクチン、キサンタンガ
ム、グルコマンナン、キチン質及びプルランから選ばれ
た少なくとも１種の天然多糖類を、アルカリの存在下或
いは非存在下に、均一に混練して得られた天然多糖類・
多価アルコール組成物の溶液を用いてカプセルを形成
し、カプセル形成と同時にまたはカプセル形成後に、該
カプセルに薬剤が通過できる複数の孔を穿設するか、或
いは腸内において穿設可能とし、該カプセル内に腸疾患
用薬剤を収納し、しかる後該カプセルを融点３５℃以上
で胃液により分解し難い素材で被覆することを特徴とす
る腸疾患用薬剤カプセルの製法。3. A polyhydric alcohol, a sugar alcohol, a monosaccharide,
Carrageenan, alginic acid, alginic acid derivative, agar, locust bean gum, guar gum, tamarind seed polysaccharide, pectin, xanthan gum, glucomannan, chitin and at least one stock solution or concentrated solution selected from disaccharides and oligosaccharides. A natural polysaccharide obtained by uniformly kneading at least one natural polysaccharide selected from pullulan in the presence or absence of an alkali.
A capsule is formed using a solution of a polyhydric alcohol composition, and at the same time as or after capsule formation, a plurality of holes through which a drug can pass is formed in the capsule, or the capsule can be formed in the intestine. A method for producing a drug capsule for enteric diseases, which comprises storing the drug for enteric diseases in the capsule and then coating the capsule with a material having a melting point of 35 ° C. or higher and difficult to decompose by gastric juice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2364090A JPH0647530B2 (en) | 1990-02-03 | 1990-02-03 | Pharmaceutical capsules for intestinal diseases and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2364090A JPH0647530B2 (en) | 1990-02-03 | 1990-02-03 | Pharmaceutical capsules for intestinal diseases and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03232815A JPH03232815A (en) | 1991-10-16 |
| JPH0647530B2 true JPH0647530B2 (en) | 1994-06-22 |
Family
ID=12116168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2364090A Expired - Fee Related JPH0647530B2 (en) | 1990-02-03 | 1990-02-03 | Pharmaceutical capsules for intestinal diseases and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0647530B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011118454A1 (en) | 2010-03-23 | 2011-09-29 | リンテック株式会社 | Solid preparation |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060011955A (en) * | 2003-04-14 | 2006-02-06 | 에프엠씨 코포레이션 | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| JPWO2004096283A1 (en) * | 2003-05-02 | 2006-07-13 | 株式会社林原生物化学研究所 | Soft capsule film and soft capsule |
| EP2111788B1 (en) | 2007-01-30 | 2014-01-08 | Olympus Medical Systems Corp. | Device for checking for lumen passage |
| WO2008093554A1 (en) | 2007-01-30 | 2008-08-07 | Olympus Medical Systems Corp. | Device for checking for lumen passage and method of producing device for checking for lumen passage |
| JP5250285B2 (en) * | 2008-03-26 | 2013-07-31 | 富士フイルム株式会社 | Oral dressing, edible container and oral product using them |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0211991B1 (en) * | 1982-07-08 | 1989-10-25 | Ab Leo | Substained release tablets and method for preparation thereof |
| JPS6229515A (en) * | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | Method for film-coating of hard capsule |
| JPS6418440A (en) * | 1987-07-10 | 1989-01-23 | Dainippon Pharmaceutical Co | Micro-capsule |
-
1990
- 1990-02-03 JP JP2364090A patent/JPH0647530B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011118454A1 (en) | 2010-03-23 | 2011-09-29 | リンテック株式会社 | Solid preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03232815A (en) | 1991-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004004331T2 (en) | Implantable pump for the treatment of obesity | |
| US6730321B2 (en) | Press coated, pulsatile drug delivery system suitable for oral administration | |
| Maroni et al. | Film coatings for oral colon delivery | |
| US6030641A (en) | Sustained release capsule and method for preparing the same | |
| JP2001511441A (en) | Pellets for treating and treating the intestinal tract | |
| EP1301178B1 (en) | Delivery device | |
| CA2014451A1 (en) | Sustained-release oral drug dosage form | |
| Belgamwar et al. | Pulsatile drug delivery system | |
| KR20080028361A (en) | Quinine-containing controlled-release formulations | |
| AU583903B2 (en) | Controlled release potassium chloride | |
| Anal | Time-controlled pulsatile delivery systems for bioactive compounds | |
| JPH07506356A (en) | Ophthalmic pharmaceutical preparation and method for producing the same | |
| JP2022104916A (en) | Self-regulating osmotic gastroretentive drug delivery systems | |
| WO1994007470A1 (en) | Article containing a core and a coating having a non constant thickness | |
| DD297559A5 (en) | Solid dosage form for pharmaceutical active ingredients | |
| Modi et al. | Pulsatile: A tool for circardian rhythm-a review | |
| US9066877B2 (en) | Bezoar-forming units for weight control | |
| JPH0647530B2 (en) | Pharmaceutical capsules for intestinal diseases and method for producing the same | |
| JP7423794B2 (en) | Sustained release composition containing liothyronine | |
| US4863743A (en) | Controlled release potassium chloride | |
| ES2248094T3 (en) | POSOLOGICAL FORM OF CONTINUOUS RELEASE WITH COAT OF LATEX AND ITS PROCEDURE OF REALIZATION. | |
| KR20090086128A (en) | Pharmaceutical composition of memantine | |
| CZ356696A3 (en) | Support of active compounds for their controlled release in gastrointestinal tract with delayed passage through pylorus | |
| EP2022494A2 (en) | Laxative preparation containing l-Arginine | |
| Pathak | Novel concept of drug delivery based on chronotherapy: a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090622 Year of fee payment: 15 |
|
| LAPS | Cancellation because of no payment of annual fees |